Intranasal nanotherapy is being built to slip past the blood-brain barrier in glioma
Glioma, especially glioblastoma, continues to resist conventional treatment because drug access to the brain is uneven, immune suppression is deep, and systemic immunotherapies rarely reach enough intracranial target tissue to matter. The central problem is not simply whether a drug works in theory. It is whether enough of it reaches the right cells inside a tumor that is already infiltrative, heterogeneous, and shielded by a partially intact blood-brain barrier and blood-tumor barrier.
Intranasal nano-immunotherapy is being developed around a practical biological idea: if therapy can enter the brain through nasal-to-brain transport routes, then nanocarriers may deliver immune-active payloads without depending entirely on vascular penetration. The review organizes the field around three levels of evidence: direct intranasal glioma nano-immunotherapy, intranasal glioma nanodelivery without proven immune reprogramming, and non-intranasal glioma nano-immunotherapy that still informs future nasal strategies. That framework matters because the translational bar for a brain tumor treatment is far higher than simple tumor uptake in a mouse.
Nose-to-brain transport offers multiple entry paths, but each route comes with constraints
After intranasal administration, therapeutic material may move through several non-mutually exclusive routes, including olfactory transport, trigeminal transport, mucosal absorption, cerebrospinal-fluid movement, and perivascular pathways. These routes are attractive for glioma because they offer repeated, noninvasive access to the central nervous system without requiring direct intracranial injection. In practical terms, the nasal cavity becomes a delivery corridor rather than just a local mucosal surface.
Particle behavior still depends on formulation details. Size, surface charge, mucoadhesion, viscosity, and deposition pattern all influence whether a nanocarrier remains in the mucus layer, crosses the epithelium, or reaches deeper brain regions. The review makes a useful distinction here: intranasal delivery does not erase barriers, it changes them. The challenge shifts from systemic BBB penetration to nasal retention, epithelial transport, and brain distribution.
Nano-carriers are being engineered to carry immune agonists, gene regulators, and microenvironment modifiers
Across the preclinical literature summarized in the review, the platforms are diverse: peptide-guided nanomicelles, lipid nanoparticles, biomimetic nanoparticles, ferritin-based nanovectors, spherical nucleic acids, extracellular vesicles, bacterial outer membrane vesicles, and stimuli-responsive systems. Their cargo design is just as varied. Some systems deliver STING or TLR agonists; others carry siRNA or CRISPR-Cas9 components; others are built to interfere with chemokine signaling, checkpoint activity, or other elements of the glioma immune niche.
This breadth is clinically important because glioma does not fail for one reason. It fails through coordinated immune exclusion, myeloid suppression, poor antigen presentation, metabolic stress, and weak innate immune sensing. Nanocarriers are attractive precisely because they can be designed to intervene at several of those layers at once. A single delivery vehicle can protect fragile cargo from degradation, target the brain or tumor, and release payloads in a controlled way once it arrives.
Myeloid suppression and T-cell exclusion remain the therapeutic targets most likely to matter
The glioma microenvironment is dominated by immune evasion. Effector-cell entry is limited, dendritic-cell activation is weak, tumor-associated macrophages and microglia sustain suppressive signaling, and checkpoint pathways blunt the response of any T cells that do arrive. In that setting, merely stimulating immunity is not enough; the immune context has to be rewritten.
Intranasal nano-immunotherapy is being positioned for exactly that task. By delivering immune-active payloads locally, these systems may activate innate sensing, reverse myeloid-mediated suppression, increase T-cell infiltration, and drive immunogenic cell death. The biological logic is straightforward. If the tumor is cold because immune cells are excluded or disabled, then a nanoplatform that reaches the intracranial niche and shifts chemokine, checkpoint, and innate-sensing pathways may make the microenvironment more permissive to antitumor immunity.
One sentence captures the field’s central promise: local delivery may create local immunity where systemic therapy has struggled to do so.
Preclinical studies show feasibility, but the translational gap remains wide
Several experimental studies anchor the rationale for this approach. Ferritin-based nanovectors have been shown to mediate nose-to-brain selective delivery to glioma, reduce tumor growth, and improve survival in glioma-bearing mice. Biomimetic nanoparticles have also been used for nose-to-brain GBM-targeted therapy, with evidence of improved mucosal permeation, controlled release, and tumor-associated targeting characteristics. Another study paired intranasal temozolomide-conjugated nanoparticles with transcranial magnetic stimulation and improved survival in GBM xenograft models, suggesting that intranasal delivery may be combined with physical enhancement strategies.
For immunotherapy specifically, cGAS-agonistic spherical nucleic acids reprogrammed the GBM immune microenvironment and promoted antitumor immunity. A separate intranasal example used a self-assembled T7 peptide-based nanomicelle to deliver siRNA through the nasal route. Together, those studies show that nose-to-brain nanoplatforms can be built not only to reach the brain, but to carry payloads that change immune behavior once there.
The biggest obstacles are dosing uncertainty, safety, and incomplete immune validation
The review is explicit about what still blocks translation. Dosing remains uncertain, especially because nasal anatomy and transport characteristics differ across species. Mucosal safety and neurological safety need more direct evaluation. Manufacturing complexity is another barrier, particularly for platforms that combine targeting ligands, nucleic acids, and stimuli-responsive features in one product.
Immune pharmacodynamics remain incomplete as well. It is not enough to show tumor shrinkage or longer survival in animals. A clinically credible platform needs evidence that it actually engages the intended immune pathway in the brain tumor microenvironment, and that the effect is durable, measurable, and safe. Without that, a treatment may look effective in a narrow preclinical setting while failing to reproduce in humans.
The review also warns against over-reading non-comparative animal data. A survival gain after intranasal dosing does not automatically prove superior pharmacokinetics, lower systemic exposure, or better selectivity unless route-to-route comparisons are directly performed.
Preclinical validation will decide whether the field moves beyond concept
The proposed next step is a structured validation framework that can answer whether these experimental systems are ready for clinically testable design. That means assessing brain delivery, tumor targeting, immune reprogramming, and safety in a way that is reproducible across models. It also means matching the delivery platform to the biology of glioma rather than assuming every nanocarrier will behave the same way once it enters the nasal cavity.
For now, intranasal nano-immunotherapy remains a compelling preclinical strategy, not a proven clinical solution. Its appeal lies in combining two difficult goals at once: bypassing a delivery barrier and reshaping an immune-resistant tumor. The remaining challenge is proving that the biology seen in animals can be translated into a treatment that is manufacturable, safe, and potent enough for human glioma.